Literature DB >> 12121791

Studies on the kinetic stabilities of the Gd(3+) complexes formed with the N-mono(methylamide), N'-mono(methylamide) and N,N"-bis(methylamide) derivatives of diethylenetriamine-N,N,N',N",N"-pentaacetic acid.

Lajos Sarka1, László Burai, Róbert Király, László Zékány, Ernõ Brücher.   

Abstract

High kinetic stability is an important requirement for the Gd(3+) complexes used as contrast enhancement agents in magnetic resonance imaging. The kinetic stabilities of the Gd(3+) complexes formed with DTPA-N-mono(methylamide) (L(3)), DTPA-N'-mono(methylamide) (L(2)) and DTPA-bis(methylamide) (L(1)) are characterized by the rates of the exchange reactions with Eu(3+) and the endogenous Cu(2+) and Zn(2+). The exchange reactions occur via the proton-assisted dissociation of the complexes and direct attack of the exchanging metal ions on the complex. On the basis of the line-shape analysis of the 1H NMR spectra of the LaL(2), obtained in the pH range 2.5-3.5, we assume that for the proton-assisted dissociation of the complexes the formation of an intermediate containing a free iminodiacetate group must be followed with the rupture of the metal-central nitrogen bond. At about pH > or = 5, the reactions between GdL(2) or GdL(3) and Cu(2+) or Zn(2+) proceed predominantly by direct reaction of the reactants, through the formation of dinuclear intermediates. The contribution of the proton-assisted dissociation is highly important for GdL(1), but its reaction with Zn(2+) is significantly slower than the reactions of GdL(2) and GdL(3). The overall rates of dissociation of GdL(1), GdL(2), GdL(3) and Gd(DTPA)(2-) through H(+) (pH 7.4), Cu(2+) (1 x 10(-6) M) and Zn(2+) (1 x 10(-5) M)-assisted reactions are surprisingly very similar. Replacement of one or two carboxylates with amide groups results in significantly decreased stability constants, but has practically no effect on the kinetic stability of the Gd(3+) complexes, indicating the lower reactivity of the amide groups with Cu(2+) and Zn(2+).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121791     DOI: 10.1016/s0162-0134(02)00418-x

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  7 in total

Review 1.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

2.  Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Authors:  Byunghee Yoo; Mark D Pagel
Journal:  Bioconjug Chem       Date:  2007-03-02       Impact factor: 4.774

Review 3.  Primer on gadolinium chemistry.

Authors:  A Dean Sherry; Peter Caravan; Robert E Lenkinski
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

4.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

5.  Gd3TCAS2: An Aquated Gd(3+)-Thiacalix[4]arene Sandwich Cluster with Extremely Slow Ligand Substitution Kinetics.

Authors:  Nobuhiko Iki; Eszter Boros; Mami Nakamura; Ryo Baba; Peter Caravan
Journal:  Inorg Chem       Date:  2016-03-28       Impact factor: 5.165

Review 6.  Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents.

Authors:  Thomas J Clough; Lijun Jiang; Ka-Leung Wong; Nicholas J Long
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

Review 7.  How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.

Authors:  Quyen N Do; Robert E Lenkinski; Gyula Tircso; Zoltan Kovacs
Journal:  Molecules       Date:  2021-12-23       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.